Table 6 Amounts necessary for the acquisition of vaccines by the PAI in Ecuador and percentage of Imports of vaccines in relation to local production, Source PAI, prepared by the Author [70]
From: Vaccine market and production capabilities in the Americas
| Vaccine name | Revolving fund via EPI | Enfarma / Inspi | % of imports 2013 | % Imports 2016 |
|---|---|---|---|---|
| BCG | $ 89.647 | 100% | 100% | |
| MMR | $ 852.194 | 100% | 100% | |
| MR | $ 105.344 | 100% | 100% | |
| Polio Vaccine | $ 402.780 | 100% | 100% | |
| Rotavirus Vaccine | $ 4.011.333 | 100% | 100% | |
| Pneumococcal vaccine | $ 819.275 | 100% | 100% | |
| Immunoglobulin HB. | $ 8.807 | 100% | 100% | |
| Chickenpox vaccine | $ 5.129.735 | 100% | 100% | |
| Yellow fever vaccine | $ 1.585.111 | 100% | 100% | |
| Influenza | $ 6.644.748 | 100% | 100% | |
| Trivalent influenza | $ 3.743.625 | 100% | 100% | |
| Pediatric trivalent influenza | $ 1.032.000 | 100% | 100% | |
| Conjugated Pneumococcal vaccine | $ 15.272.250 | 100% | 100% | |
| DT adults | $ 247.200 | 39% | 100% | |
| Anti-meningococcal | $ 29.960 | 100% | 100% | |
| Hep B | $ 292.500 | 100% | 100% | |
| Pediatric Hep B | $ 25.500 | 100% | 100% | |
| Pentavalent | $ 3.431.000 | 100% | 100% | |
| DPT | $ 92.000 | 0% | 100% | |
| DT Pediatric | $ 72.000 | 0% | 100% | |
| Total | $ 39.696.850 | $ 4.190.160 | 88% | 100% |